Post by Novo Nordisk

The European Medicines Agency has approved an update to our obesity injection’s product information, allowing it to be kept at controlled temperatures up to 30°C for up to 48 hours during delivery. We are dedicated to improving the access to our products. With this update, our obesity injection is the first GLP-1 for weight management in Europe with this added delivery flexibility - potentially helping to simplify how medicines are delivered by pharmacies and online partners and enabling more convenient, discreet home delivery options. Learn more in the press release here: https://lnkd.in/eaDjubRt   #PRESS